Astellas establishes Regenerative Medicine Unit

Published: 2-Apr-2014
Research & Development Pharmaceutical Cell & Gene Therapy

Will expand the company\'s research into regenerative medicine and cell therapy


Japanese pharmaceutical company Astellas has announced the launch of its new regenerative medicine business unit, which commenced operations on 1 April.

The new division aims to undertake innovative regenerative medicine studies and build an autonomous and highly agile research management structure, reporting directly to Astellas' Senior Vice-President and President of drug discovery research.

Its key priorities will be to establish and maintain technology platforms involving regenerative medicine and cell therapy, taking advantage of the multifunctional characteristics of cells to produce more effective treatments than are currently available.

Astellas stated last year that it would expand its presence in the regenerative medicine field, with its new cell therapy focus coming in addition to the conventional pharmaceutical research that it undertakes.

  • Companies:
  • Astellas Pharma
See more

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

Read more
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone

Trending Articles

  1. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  2. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  3. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  4. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  5. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Research & Development

Astellas Pharma doses first patient in Phase III trial for Fezolinetant

Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer
Manufacturing

Astellas begins construction of manufacturing site in Tralee

600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Ingredients

Therapeutic: zolbetuximab for gastric cancer

Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Research & Development

Astellas invests $13m in cell and gene therapy innovation incubators

Japanese Astellas’ nearly $13m will make it a Founding Sponsor of LabCentral's new incubator with a core lab space for process development studies and a non-GMP pilot plant
Finance

Astellas to buy Ocata Therapeutics

New step forward in ophthalmology and stem cell therapy
Subscribe now